Blackstone to provide $1.5 billion for Pfizer's obesity drug development
BX Blackstone Inc
$120.19 +1.39%
View chart & analysis → - 1Pfizer has secured $1.5 billion from Blackstone Life Sciences to accelerate the clinical development of berobenatide.
- 2Blackstone plans to fund the development costs of berobenatide through 2028.
- 3Pfizer acquired the asset previously known as MET097i as part of its $10 billion acquisition of Metsera in December 2025.
So what's the key point?
Blackstone has decided to help Pfizer develop an obesity treatment. It will provide $1.5 billion in funding through 2028.
Source Pharmaceutical Technology +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.